Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04262466 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
NotablePrimary completion date: Feb 2026 to Oct 2026v21Show 4 more changesShow less
Trial status: Recruiting to Active, Not Recruiting
Enrollment target: estimated 727 to confirmed 410
Study completion date: Aug 2026 to Dec 2027
Site details revised at 76 of 76 sites
MinorSite details revised at 12 of 76 sites
Eligibility criteria expanded, about 1 word
v20
MinorSite details revised at 7 of 76 sitesv19
MinorStudy sites: 68 to 76v18Show 5 more changesShow less
Primary completion date: Jun 2026 to Feb 2026
Study completion date: Jun 2026 to Aug 2026
Interventions: IMC-F106C (Drug), IMC-F106C and bevacizumab (Drug), IMC-F106C and chemotherapy (Drug), IMC-F106C and kinase inhibitors (Drug), IMC-F106C… to Brenetafusp (Drug), Brenetafusp and bevacizumab (Drug), Brenetafusp and chemotherapy (Drug), Brenetafusp and kinase inhibitors (Drug)…
Secondary endpoints revised (12)
Study description revised
NotableEnrollment target: 170 to 727v17Show 9 more changesShow less
Primary completion date: Feb 2024 to Jun 2026
Primary endpoints: 7 to 10
Study sites: 33 to 68
Study completion date: Feb 2026 to Jun 2026
Interventions: IMC-F106C (Drug), IMC-F106C and atezolizumab and pembrolizumab (Drug), IMC-F106C and chemotherapy (Drug), IMC-F106C and tebentafusp (Drug) to IMC-F106C (Drug), IMC-F106C and bevacizumab (Drug), IMC-F106C and chemotherapy (Drug), IMC-F106C and kinase inhibitors (Drug), IMC-F106C…
Eligibility criteria shortened, about 16 words
Secondary endpoints: 11 to 12
Study description shortened, about 6 words
Study arms: 4 to 5
Show 15 earlier versionsHide 15 earlier versions
MinorStudy sites: 30 to 33v16
MinorRe-verified, no change to tracked fieldsv15
MinorStudy sites: 14 to 30v14
MinorStudy sites: 13 to 14v13Show 4 more changesShow less
Interventions: IMC-F106C (Drug), anti-PD(L)1 (Drug) to IMC-F106C (Drug), IMC-F106C and atezolizumab and pembrolizumab (Drug), IMC-F106C and chemotherapy (Drug), IMC-F106C and tebentafusp (Drug)
Eligibility criteria expanded, about 17 words
Study arms: 3 to 4
Study description expanded, about 4 words
NotablePrimary completion date: Feb 2022 to Feb 2024
Study completion date: Feb 2024 to Feb 2026
Site contacts updated at 2 of 13 sites
v12
MinorSite contacts updated at 5 of 13 sites
Study description shortened, about 5 words
v11
MinorSite contacts updated at 2 of 13 sitesv10
MinorSite details revised at 5 of 13 sitesv9
MinorStudy sites revised (13)v8
MinorStudy sites: 12 to 13v7
MinorStudy sites: 11 to 12
Eligibility criteria revised
v6
MinorStudy sites: 4 to 11v5
MinorStudy sites: 1 to 4v4
MinorStart date changed from estimate of Feb 2020 to Feb 25, 2020v3
NotableTrial status: Not Yet Recruiting to Recruiting
Site details revised
v2
MinorStudy First Submitted
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Brenetafusp (IMC-F106C) is an immune-mobilizing monoclonal T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated antigen PRAME. This is a first-in-human trial designed to evaluate the safety and efficacy of brenetafusp in adult participants who have the appropriate HLA-A2 tissue marker and whose cancer is positive for PRAME.